Synergy Asset Management LLC Sells 10,070 Shares of AbbVie Inc. $ABBV

Synergy Asset Management LLC reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 9.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 100,679 shares of the company’s stock after selling 10,070 shares during the period. AbbVie makes up approximately 2.4% of Synergy Asset Management LLC’s holdings, making the stock its 12th biggest holding. Synergy Asset Management LLC’s holdings in AbbVie were worth $23,004,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. bought a new stake in AbbVie in the 2nd quarter valued at $26,000. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter worth about $26,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the 3rd quarter worth about $31,000. Caitlin John LLC acquired a new stake in shares of AbbVie in the 3rd quarter valued at about $33,000. Finally, Delos Wealth Advisors LLC bought a new stake in shares of AbbVie in the second quarter valued at about $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 1.9%

ABBV stock opened at $211.12 on Friday. The company has a market cap of $373.29 billion, a price-to-earnings ratio of 89.46, a P/E/G ratio of 0.72 and a beta of 0.34. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The business has a 50 day moving average price of $222.06 and a two-hundred day moving average price of $224.53.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the business posted $2.16 EPS. The business’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics will present 21 evidence-based e-posters at AMWC 2026, highlighting clinical and real‑world data that support product leadership and could help maintain premium pricing and practitioner demand. Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
• Positive Sentiment: Allergan is promoting a new “Undetectable” era for JUVÉDERM at AMWC, a marketing/product push that may support volume and pricing for AbbVie’s largest aesthetics franchise. Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
• Positive Sentiment: Erste Group nudged up its FY2027 EPS forecast for AbbVie (to $16.16), a small analyst lift that signals growing analyst confidence in longer‑term earnings power. Erste Group Bank upped their FY2027 earnings per share (EPS) estimates for AbbVie
• Positive Sentiment: AbbVie’s official partnership with MLB (seasonal marketing/awareness) can broaden brand visibility for patient and provider audiences and is a supportive commercial catalyst. How AbbVie’s official partnership with MLB will unfold over the course of the season
• Neutral Sentiment: Zacks and other outlets note elevated investor attention on AbbVie and publish comparative takes (e.g., vs. Eli Lilly) — increased search/coverage can raise short-term volatility but also liquidity. Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
• Neutral Sentiment: Coverage labeling AbbVie as a candidate in the psychedelics/psychiatry theme (coverage of bretisilocin acquisition) may attract growth‑oriented investors, but clinical risk and long timelines keep impact uncertain. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Negative Sentiment: Analyst commentary and valuation pieces point to recent share weakness (declines over the past week/month) and ongoing valuation questions despite multi-year gains, which can cap near‑term upside. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. UBS Group cut their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.